A Adenis

Summary

Affiliation: Centre Oscar Lambret
Country: France

Publications

  1. doi request reprint Palliative chemotherapy does not improve survival in metastatic esophageal cancer
    Antoine Adenis
    Faculté Libre de Médecine, Department of Gastrointestinal and Urological Oncology, Catholic University, Lille, France
    Oncology 79:46-54. 2010
  2. pmc Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program
    Antoine Adenis
    Medical Oncology, Centre Oscar Lambret and Catholic University, Lille, France
    BMC Cancer 16:412. 2016
  3. pmc The off-label use of targeted therapies in sarcomas: the OUTC'S program
    Lauriane Eberst
    Centre Leon Berard, 28 rue Laennec 69 373, Lyon Cedex 08, France
    BMC Cancer 14:870. 2014
  4. pmc Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group
    Thanh Khoa Huynh
    Service d Oncologie Medicale, CHU Timone, AP HM, Marseille, and Aix Marseille Universite, Marseille, France
    BMC Cancer 14:156. 2014
  5. pmc Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome
    Antoine Adenis
    Gastrointestinal Oncology Department, Centre Oscar Lambret, 3 rue Combemale, 59020 Lille Cedex, France
    BMC Cancer 13:413. 2013
  6. pmc Image-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking
    Hajer Jarraya
    Department of Radiology, CLCC Oscar Lambret, 3 Rue Frederic Combemale, BP 307, Lille Cedex, 59020, France
    Radiat Oncol 8:24. 2013
  7. pmc Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADCI002
    Guillaume Piessen
    Department of Digestive and Oncological Surgery, University Hospital of Lille, F 59037 Lille, France
    BMC Cancer 13:281. 2013
  8. doi request reprint Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors
    Antoine Adenis
    Medical Oncology Department, Centre Oscar Lambret, BP307, 59020, Lille, France
    Med Oncol 29:3003-8. 2012
  9. pmc Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival
    Lucie Oberic
    Institut Gustave Roussy, Villejuif, France
    Radiat Oncol 6:124. 2011
  10. pmc Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
    Aurore Blesius
    Department of Medicine, Institut Roussy, Villejuif, France
    BMC Cancer 11:72. 2011

Detail Information

Publications72

  1. doi request reprint Palliative chemotherapy does not improve survival in metastatic esophageal cancer
    Antoine Adenis
    Faculté Libre de Médecine, Department of Gastrointestinal and Urological Oncology, Catholic University, Lille, France
    Oncology 79:46-54. 2010
    ..The role of chemotherapy in metastatic esophageal carcinoma (MEC) remains a matter of debate. The aim of this retrospective study was to analyze the survival impact of chemotherapy after stratification for prognostic factors...
  2. pmc Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program
    Antoine Adenis
    Medical Oncology, Centre Oscar Lambret and Catholic University, Lille, France
    BMC Cancer 16:412. 2016
    ..We evaluated survival and safety outcomes in patients treated with regorafenib in a real-life setting...
  3. pmc The off-label use of targeted therapies in sarcomas: the OUTC'S program
    Lauriane Eberst
    Centre Leon Berard, 28 rue Laennec 69 373, Lyon Cedex 08, France
    BMC Cancer 14:870. 2014
    ..The French Sarcoma Group - Bone Tumor Study Group (GSF-GETO) created a national registry to evaluate the outcome of patients treated with off-label TTs...
  4. pmc Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group
    Thanh Khoa Huynh
    Service d Oncologie Medicale, CHU Timone, AP HM, Marseille, and Aix Marseille Universite, Marseille, France
    BMC Cancer 14:156. 2014
    ..Rectal and pararectal gastrointestinal stromal tumors (GISTs) are rare. The optimal management strategy for primary localized GISTs remains poorly defined...
  5. pmc Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome
    Antoine Adenis
    Gastrointestinal Oncology Department, Centre Oscar Lambret, 3 rue Combemale, 59020 Lille Cedex, France
    BMC Cancer 13:413. 2013
    ..To identify predictors of long-term outcome for patients with clinical complete response (cCR) after definite chemoradiotherapy (CRT) or radiation therapy (RT) for oesophageal cancer (EC)...
  6. pmc Image-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking
    Hajer Jarraya
    Department of Radiology, CLCC Oscar Lambret, 3 Rue Frederic Combemale, BP 307, Lille Cedex, 59020, France
    Radiat Oncol 8:24. 2013
    ..To describe post-CyberKnife® imaging characteristics of liver metastases as an aid in assessing response to treatment, and a novel set of combined criteria (CC) as an alternative to response according to change in size (RECIST)...
  7. pmc Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADCI002
    Guillaume Piessen
    Department of Digestive and Oncological Surgery, University Hospital of Lille, F 59037 Lille, France
    BMC Cancer 13:281. 2013
    ..Evidence is accruing that signet ring cell carcinomas may have inherent chemo resistance leaving many clinicians unsure of the benefits of delaying surgery to pursue a neoadjuvant approach...
  8. doi request reprint Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors
    Antoine Adenis
    Medical Oncology Department, Centre Oscar Lambret, BP307, 59020, Lille, France
    Med Oncol 29:3003-8. 2012
    ..We found increased CK in about one-third of patients under TKIs for solid tumors, including 3% of patients with CK as high as 2.5-5 times ULN...
  9. pmc Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival
    Lucie Oberic
    Institut Gustave Roussy, Villejuif, France
    Radiat Oncol 6:124. 2011
    ..We report here the results of the docetaxel plus 5 FU regimen stopped according to the interim analysis. The docetaxel plus cisplatin arm was continued...
  10. pmc Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
    Aurore Blesius
    Department of Medicine, Institut Roussy, Villejuif, France
    BMC Cancer 11:72. 2011
    ..We analyzed the outcome of patients with non metastatic locally advanced primary GIST treated with IM within the prospective BFR14 phase III trial...
  11. ncbi request reprint Acute respiratory disease syndrome with preoperative chronomodulated chemoradiotherapy in patients with esophageal cancer. Early termination of a phase I trial
    A Adenis
    Department of Gastrointestinal and Urological Oncology, Centre Oscar Lambret, Lille, France
    Eur J Surg Oncol 34:30-5. 2008
    ..Without definitively ruling out any possible impact of chronomodulation in that setting, our data reinforce the need of a better selection of patients aimed to be treated by CRT plus surgery...
  12. ncbi request reprint [Esophageal cancers]
    A Adenis
    Département de Cancérologie Digestive et Urologique, Centre Oscar Lambret, rue Frederic Combemale, 59020 Lille Cedex
    Bull Cancer 88:965-83. 2001
    ..Finally, the symptomatic treatment of dysphagia might not be ignored either in locally, locally advanced, or in metastatic disease...
  13. ncbi request reprint [Targeting the epidermal growth factor receptor in colorectal cancer: clinical results]
    Antoine Adenis
    Département de Cancérologie Digestive et Urologique, Centre Oscar Lambret, BP 307, 59020 Lille Cedex
    Bull Cancer 92:S21-8. 2005
    ..At this point of the clinical development of these all EGFR inhibitors (monoclonal antibodies or tyrosine kinase inhibitors) in MCRC, informative data from randomized studies are urgently needed...
  14. ncbi request reprint [Inhibitors of epidermal growth factor receptor and colorectal cancer]
    Antoine Adenis
    Département de Cancérologie Digestive et Urologique, Centre Oscar Lambret, BP 307, 59020 Lille
    Bull Cancer 90:S228-32. 2003
    ..Finally, the promising activity of these EGF-R inhibitors has to be confirmed throughout randomized studies...
  15. doi request reprint Imatinib in gastrointestinal stromal tumor: does treatment duration matter?
    Antoine Adenis
    Department of Medical Oncology, Centre Oscar Lambret, Lille, France
    Oncology 77:157-61. 2009
    ..This review provides a clinical perspective on the available data, evidence- or expert-based, for calculating the optimal treatment duration with imatinib...
  16. ncbi request reprint Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial
    J Domont
    Institut Gustave Roussy, Villejuif, France Centre Leon Berard, Lyon, France Institut Bergonié, Bordeaux, France Centre Oscar Lambret, Lille, France Centre Alexis Vautrin, Nancy, France Institut Paoli Calmettes, Marseille, France La Timone University Hospital, Marseille, France Centre Val d Aurelle, Montpellier, France Institut Claudius Regaud, Toulouse, France Centre René Gauducheau, Nantes, France
    J Clin Oncol 29:10054. 2011
    ..However, the tumor volume of residual lesions at the time of IM interruption and at the time of the best response when IM was reintroduced could influence the long term OS...
  17. ncbi request reprint Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study)
    M Ducreux
    Institut Gustave Roussy, Villejuif, France Centre Oscar Lambret, Lille, France Centre Antoine Lacassagne, Nice, France Centre Eugène Marquis, Rennes, France Centre Georges François Leclerc, Dijon, France Centre Val d Aurelle, Montpellier, France Institut Curie, Paris, France FNCLCC, Paris, France Centre Alexis Vautrin, Nancy, France
    J Clin Oncol 27:4086. 2009
    ..This randomized non-comparative phase II trial evaluated the efficacy and safety of BEV in combination with either XELIRI or FOLFIRI as first-line therapy for mCRC...
  18. ncbi request reprint Outcomes for patients with advanced GIST achieving a complete remission (CR) with imatinib (IM): Results from the prospective randomized phase III trial of the French Sarcoma Group
    A Cioffi
    Institut Gustave Roussy, Villejuif, France Centre Leon Berard, Lyon, France Institut Bergonié, Bordeaux, France Centre Alexis Vautrin, Nancy, France La Timone, Marseille, France Institut Paoli Calmettes, Marseille, France Centre Oscar Lambret, Lille, France
    J Clin Oncol 26:10550. 2008
    ..The pattern of response to IM is heterogeneous. Patient (pt) characteristics and outcome of pts experiencing a CR under IM are unknown...
  19. ncbi request reprint Does interruption of imatinib (IM) in responding patients after three years of treatment influence outcome of patients with advanced GIST included in the BFR14 trial?
    A Adenis
    Centre Oscar Lambret, Lille, France Centre Leon Berard, Lyon, France Institut Bergonié, Bordeaux, France Centre Alexis Vautrin, Vandoeuvre les Nancy, France Hopital la Timone, Marseille, France Centre Paoli Calmettes, Marseille, France Centre Leon Berard and Hopital Edouard Herriot, Lyon, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 26:10522. 2008
    ..The impact of treatment interruption at later time points on progression-free survival (PFS) and overall survival (OS) is unknown...
  20. ncbi request reprint Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: Updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival
    A Le Cesne
    Institut Gustave Roussy, Villejuif, France Centre Leon Berard, Lyon, France Institut Bergonié, Bordeaux, France Centre Oscar Lambret, Lille, France Centre Alexis Vautrin, Nancy, France Institut Paoli Calmettes, Marseille, France La Timone University Hospital, Marseille, France Centre Val d Aurelle, Montpellier, France Institut Claudius Regaud, Toulouse, France Centre René Gauducheau, Nantes, France
    J Clin Oncol 29:10015. 2011
    ..The impact of IM interruption on secondary resistance and overall survival (OS) with longer-term follow-up was unclear...
  21. ncbi request reprint Neoadjuvant imatinib in patients with locally advanced GIST in the prospective BFR14 trial
    P A Cassier
    Hopital Edouard Herriot, Lyon, France Hôpital de la Timone, Marseille, France Centre Leon Berard, Lyon, France Centre Oscar Lambret, Lille, France Institut Bergonié, Bordeaux, France Institut Paoli Calmette, Marseille, France Centre Alexis Vautrin, Nancy, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:10551. 2009
    ..We sought to assess the outcome of patients with locally advanced primary GIST tumors without metastases treated with IM in the neoadjuvant setting within the prospective BFR14 phase III trial...
  22. pmc A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours
    A Adenis
    1 Department of Medical Oncology, Centre Oscar Lambret, 3, rue F Combemale, Lille, France 2 Catholic University of Lille, Medical School, Lille, France
    Br J Cancer 109:2574-8. 2013
    ..Preclinical findings suggest that imatinib mesylate (IM) and metronomic cyclophosphamide (MC) combination provides synergistic antiangiogenic activity on both pericytes and endothelial cells...
  23. doi request reprint Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab
    D Malka
    Gastrointestinal Oncology Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 23:919-27. 2012
    ..We investigated whether circulating endothelial cells (CECs) predict clinical outcome of first-line chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC) patients...
  24. ncbi request reprint Circulating endothelial cell (CEC) monitoring in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line bevacizumab (BEV)-based combination regimens: Results of the randomized phase II FNCLCC-ACCORD 13/0503 trial
    F Farace
    Institut Gustave Roussy, Villejuif, France Centre Oscar Lambret, Lille, France Centre Eugène Marquis, Rennes, France Institut Curie, Paris, France Centre Alexis Vautrin, Nancy, France FNCLCC, Paris, France
    J Clin Oncol 27:4071. 2009
    ..4071 Background: There is no validated biomarker to predict the efficacy of BEV, an anti-VEGF monoclonal antibody. Rare cell subpopulations such as CEC are good candidates...
  25. ncbi request reprint Oral metronomic chemotherapy using cyclophosphamide in metastatic patients (pts) after standard treatment: Results of a randomized phase II trial
    S Clisant
    Centre Oscar Lambret, Lille, France Hopital Saint Vincent, Lille, France CHRU, Lille, France
    J Clin Oncol 27:e13519. 2009
    ..Anecdotal responses have been reported with each treatment. We hypothesized that each treatment offer disease control without significant severe toxicity...
  26. ncbi request reprint Oral metronomic cyclophosphamide (OMC) versus megestrol acetate (MA) among patients with advanced, refractory and progressive solid tumours: A randomized phase II study
    N Penel
    Centre Oscar Lambret, Lille, France CHRU Lille, Lille, France
    J Clin Oncol 26:20603. 2008
    ..Anecdotal responses have been reported with both treatments. We hypothesize that both treatments may offer stable disease (SD) without any severe toxicity among such pts...
  27. ncbi request reprint Final results of a multicenter phase II trial assessing sorafenib (S) in combination with irinotecan (i) as second- or later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS-mutated tumors (mt; NEXIRI)
    M Ychou
    CRLC Val d Aurelle, Montpellier, France University Hospital Robert Debre, Reims, France Centre Antoine Lacassagne, Nice, France Centre Oscar Lambret, Lille, France Centre René Gauducheau, Nantes, France Hôpital European Georges Pompidou, Paris, France Centre Leon Berard, Lyon, France APHM La Timone, Marseille, France Centre Alexis Vautrin, Vandoeuvre les Nancy, France Centre François Baclesse, Caen, France Biology Department, CRLC Val d Aurelle, Montpellier, France Pathology Depatment, CRLC Val d Aurelle, Montpellier, France APHP, Hopital Europeen Georges Pompidou, Paris, France
    J Clin Oncol 29:e14002. 2011
    ..The aim of this phase II trial was to evaluate the disease control rate (DCR) of i combined with S as second- or later line treatment (tt) in mCRC pts with KRAS mt...
  28. ncbi request reprint Masatinib mesylate in imatinib-naive locally advanced or metastatic gastrointestinal stromal tumor (GIST): Results of the French Sarcoma Group phase II trial
    A Le Cesne
    Institut Gustave Roussy, Villejuif, France Centre Leon Berard, Lyon, France Institut Bergonié, Bordeaux, France Hopital Robert Debré, Reims, France Centre Oscar Lambret, Lille, France AB Science, Paris, France Hôpital Necker, Paris, France
    J Clin Oncol 27:10507. 2009
    ..Masatinib also inhibits PDGFR and FGFR3. This multicenter phase II study evaluated the efficacy and safety of masatinib as a first-line treatment of advanced GIST...
  29. pmc Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial
    E Samalin
    Medical Oncology Department, institut du cancer de Montpellier, 34298 Montpellier, France
    Br J Cancer 110:1148-54. 2014
    ....
  30. pmc Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer
    T Conroy
    Centre Alexis Vautrin, Department of Medical Oncology, Nancy University, 6 avenue de Bourgogne, 54511 Vandœuvre lès Nancy Cedex 54511, France
    Br J Cancer 103:1349-55. 2010
    ..A randomised phase II trial was initiated to assess the feasibility and efficacy in terms of the endoscopic complete response rate (ECRR) of radiotherapy with oxaliplatin, leucovorin and fluorouracil (FOLFOX4) or cisplatin/fluorouracil...
  31. ncbi request reprint Gastrointestinal stromal tumors (GIST) of the duodenum: A French Sarcoma Group (FSG) retrospective review of 90 patients (pts)
    F Duffaud
    La Timone University Hospital, Marseille, France Centre Leon Berard, Lyon, France Medical Oncology Department, Institut Gustave Roussy, Villejuif, France University Hospital La Timone, Marseille, France Centre Eugène Marquis, Rennes, France University Hospital Robert Debre, Reims, France Centre Jean Perrin, Clermont Ferrand, France Centre Alexis Vautrin, Vandoeuvre les Nancy, France Medical Oncology Department, AP HP, Salpetriere Hospital, University Paris VI, Paris, France Institut Paoli Calmettes, Marseille, France Institut Bergonié, Bordeaux, France Institut de Cancerologie de la Loire, St Priest en Jarez, France CHU, Besancon, France Centre Georges François Leclerc, Dijon, France Centre Oscar Lambret, Lille, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 29:10053. 2011
    ..10053 Background: Duodenal GIST (D-GIST) represents ≤ 5% of all GISTs, and clinicopathologic data are reported only from small series. We conducted a retrospective analysis of duodenal GIST over the past 17 years...
  32. ncbi request reprint Influence of complete resection of residual disease in responding patients to imatinib (IM) on the outcome of pts with advanced GIST: The experience of the BFR14 trial of the French Sarcoma Group
    E Stoeckle
    Institut Bergonie, Bordeaux, France Centre Leon Berard, Lyon, France Centre Alexis Vautrin, Nancy, France Hopitaux de Marseille, Marseille, France Centre Paoli Calmettes, Marseille, France Centre Oscar Lambret, Lille, France Hôpital Edouard Herriot, Lyon, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 26:10549. 2008
    ..The impact of resection of residual disease in responding patients (pts) on progression-free survival (PFS) remains controversial...
  33. ncbi request reprint Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with 5FU plus irinotecan plus leucovorin (FOLFIRI) or capecitabine plus irinotecan XELIRI plus bevacizumab
    J Ichanté
    Institut Gustave Roussy, Villejuif, France Centre Oscar Lambret, Lille, France Centre Antoine Lacassagne, Nice, France Centre Eugène Marquis, Rennes, France Georges François Leclerc Cancer Center, Dijon, France Institut Gustave Roussy, Villejuif, France Oncology Department, Montpellier, France Institut Curie, Paris, France BECT de la FNCLCC, Paris, France Centre Alexis Vautrin, Vandoeuvre les Nancy, France
    J Clin Oncol 29:e14041. 2011
    ..This study has for aim to evaluate the impact of ETS on long-term outcome in patients (pts) receiving irinotecan based CT + bev...
  34. ncbi request reprint Outcome of patients with advanced GIST achieving a complete remission (CR) with imatinib (IM) before interruption: Pooled analysis of two consecutive prospective randomizations of the French Sarcoma Group BFR14 phase III trial
    C Chevreau
    Institut Claudius Regaud, Toulouse, France Centre Leon Berard, Lyon, France Institut Bergonié, Bordeaux, France Centre Oscar Lambret, Lille, France Centre Alexis Vautrin, Nancy, France CHU la Timone, Marseille, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:10549. 2009
    ..IM interruption in responding patients after 1 and 3 yrs of treatment results in a high risk of rapid progression after a few months. The influence of pattern of response on PFS before IM discontinuation is unknown...
  35. ncbi request reprint Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival
    T Conroy
    Department of Medical Oncology, Centre Alexis Vautrin, Vandoeuvre les Nancy, France
    Ann Oncol 13:721-9. 2002
    ....
  36. ncbi request reprint Definition of an imatinib trough concentration threshold in the treatment of advanced gastrointestinal stromal tumors (GIST)
    M Molimard
    Groupe Hospitalier Pellegrin, Bordeaux, France Department of Pharmacology Universitary Hospital of Bordeaux, University of Bordeaux, INSERM U657, Bordeaux, France Universite V Segalen Service de Pharmacologie, Bordeaux, France Institut Bergonié, Bordeaux, France Institut Claudius Regaud, Toulouse, France La Timone University Hospital, Marseille, France Centre Alexis Vautrin, Nancy, France Centre Val d Aurelle, Montpellier, France Centre Oscar Lambret, Lille, France Centre Leon Berard, Lyon, France University Hospital Robert Debre, Reims, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 29:10013. 2011
    ..We prospectively performed routine analysis of I in advanced GIST pts in which we investigated the relationships between Cmin and progression-free survival (PFS)...
  37. ncbi request reprint Determinants of accrual period of time in dose escalating phase I trials
    E Dansin
    Centre Oscar Lambret, Lille, France
    J Clin Oncol 27:2518. 2009
    ..2518 Background: New drug development is a time- and resource-consuming process. Phase 1 trials constitute a major key- step of this development. Shortening the accrual time may improve this process...
  38. ncbi request reprint Who are the long responders to imatinib (IM) in patients with advanced GIST? Results of the BFR14 prospective French Sarcoma Group randomized phase III trial
    A Blesius
    Medical Oncology Department, Institut Gustave Roussy, Villejuif, France The Royal Marsden Hospital, Sutton, United Kingdom Centre Léon Bérard, Lyon, France Institut Bergonié, Bordeaux, France Centre Oscar Lambret, Lille, France Centre Alexis Vautrin, Nancy, France Institut Paoli Calmettes, Marseille, France University Hospital La Timone, Marseille, France Centre Val d Aurelle, Montpellier, France Institut Claudius Regaud, Toulouse, France Centre René Gauducheau, Nantes, France Department of Pathology, Ambroise Pare Hospital, Boulogne, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 29:10048. 2011
    ..10048 Background: The aim of this work was to characterize patient (pts) characteristics and the mutational status of GIST who benefit the most from IM in term of prolonged response and overall survival...
  39. ncbi request reprint Time to secondary resistance (TSR) after interruption of imatinib: Updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival
    F Duffaud
    French Sarcoma Group Hôpital la Timone, Marseille, France Centre Leon Berard, Lyon, France Institut Bergonié, Bordeaux, France Centre Oscar Lambret, Lille, France Centre Alexis Vautrin, Nancy, France Institut Paoli Calmettes, Marseille, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:10508. 2009
    ..The impact of IM re-introduction at progression remains unknown regarding the impact of the interruption on the TSR...
  40. pmc Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial
    A Adenis
    Department of Gastrointestinal Oncology, Centre Oscar Lambret, Lille
    Ann Oncol 25:1762-9. 2014
    ..Masitinib was evaluated in patients with advanced GIST after imatinib failure or intolerance...
  41. ncbi request reprint Quantitative density evaluation of liver metastases on CT scan: A new tool to evaluate early the benefit of bevacizumab plus chemothrapy regimen
    E Assenat
    CRLC Val d Aurelle, Montpellier, France CHU Saint Eloi, Montpellier, France Institut Gustave Roussy, Villejuif, France Biostatistics Unit, CRLC Val d Aurelle, Montpellier, France Centre Oscar Lambret, Lille, France CHU Amiens, Amiens, France Centre Eugène Marquis, Rennes, France Centre Antoine Lacassagne, Nice, France Institut Curie, Paris, France
    J Clin Oncol 29:e14015. 2011
    ....
  42. ncbi request reprint A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial
    F Viret
    Institut Paoli Calmettes, Marseille, France Centre Val d Aurelle, Montpellier, France Institut Gustave Roussy, Villejuif, France Centre René Gauducheau, Saint Herblain, France Centre Oscar Lambret, Lille, France Centre Alexis Vautrin, Nancy, France Hopital Lyon Sud, Lyon, France Centre Paul Papin, Angers, France FNCLCC, Paris, France
    J Clin Oncol 27:4625. 2009
    ..The purpose of this phase II trial was to determine the efficacy and the toxicity of radiotherapy and docetaxel and cisplatin in histologically proven adenocarcinoma of the pancreas...
  43. ncbi request reprint Overall survival benefit with masitinib mesylate in imatinib-naive, locally advanced, or metastatic gastrointestinal stromal tumor (GIST): 4-years follow-up of the French Sarcoma Group phase II trial
    J Blay
    Universite Claude Bernard Lyon I, Lyon, France Institut Gustave Roussy, Villejuif, France Institut Bergonié, Bordeaux, France University Hospital Robert Debre, Reims, France Centre Oscar Lambret, Lille, France AB Science, Paris, France APHP CHU Necker, Paris, France
    J Clin Oncol 29:85. 2011
    ..This multicenter phase II study evaluated efficacy and safety of masitinib as a first-line treatment of advanced GIST...
  44. pmc Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care
    N Penel
    Centre Oscar Lambret, Lille, France
    Br J Cancer 102:1207-12. 2010
    ..To evaluate the antitumour activity and safety of metronomic cyclophosphamide vs megestrol acetate in progressive and advanced cancer patients having exhausted all effective therapies under standard care...
  45. doi request reprint Cancer-associated hypercalcaemia in squamous-cell malignancies: a survival and prognostic factor analysis
    F Le Tinier
    Medical Oncology Department, Centre Oscar Lambret, Lille, France
    Int J Oral Maxillofac Surg 40:938-42. 2011
    ..The bedside prognostic score that the authors developed can help to anticipate patients' prognosis and adapt the treatment. This score needs to be validated on an independent cohort...
  46. doi request reprint Factors favouring palliative treatment multidisciplinary decisions for newly diagnosed visceral and soft tissue sarcomas
    N Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Equipe d Accueil 2694 Santé Publique, Epidémiologie et modélisation des maladies chroniques, université Lille II, Lille, France
    Clin Oncol (R Coll Radiol) 20:523-7. 2008
    ..The aim of this retrospective study was to establish the rationale parameters that justify this decision for newly diagnosed sarcomas...
  47. doi request reprint [Treatment of adult patients with metastatic sarcoma: current shift in concepts]
    N Penel
    Centre Oscar Lambret, Département de Cancérologie Générale, 3, rue F Combemale, 59020 Lille, France
    Bull Cancer 97:687-91. 2010
    ....
  48. ncbi request reprint [GIST: imaging findings]
    S Taieb
    Departement d Imagerie, Centre Oscar Lambret 59020 Lille cedex
    J Chir (Paris) 145:6S12-7. 2008
    ....
  49. ncbi request reprint Angiosarcomas and taxanes
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue F Combemale, Lille 59020, France
    Curr Treat Options Oncol 8:428-34. 2007
    ..Further clinical studies are needed to confirm clinic impact of weekly paclitaxel on survival and to assess the role of taxanes in the multidisciplinary treatment of AS...
  50. ncbi request reprint External beam radiation therapy followed by high-dose-rate brachytherapy for inoperable superficial esophageal carcinoma
    David Pasquier
    Department of Radiotherapy, Centre Oscar Lambret, University Lille II, Lille, France
    Int J Radiat Oncol Biol Phys 65:1456-61. 2006
    ..The aim of this study was to retrospectively evaluate the feasibility, efficacy, and tolerance of external beam radiotherapy followed by high-dose-rate brachytherapy in inoperable patients with superficial esophageal cancer...
  51. ncbi request reprint Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France
    Support Care Cancer 16:387-92. 2008
    ..Cancer-associated hypercalcemia (CAH) is the most frequent metabolic disorder in cancer patients. We retrospectively reviewed the outcome and prognostic factors for patients with CAH being treated with standard intravenous disphosphonates...
  52. doi request reprint Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue F Combemale, 59020, Lille, France
    Invest New Drugs 28:839-43. 2010
    ..New drug development is a time- and resource-consuming process. Phase 1 trials constitute a major key-step of this development. Shortening the accrual time is of major importance...
  53. pmc Development and validation of a bedside score to predict early death in cancer of unknown primary patients
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France
    PLoS ONE 4:e6483. 2009
    ..We have investigated predictors of 90-day-mortality in a large cohort of non-specific cancer of unknown primary patients...
  54. doi request reprint Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer
    Mohamed Hebbar
    Medical Oncology Unit, University Hospital, Lille, France
    Oncology 73:185-91. 2007
    ..To identify easily available predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer...
  55. doi request reprint Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue F Combemale, Lille, France
    Invest New Drugs 28:76-82. 2010
    ..Given the lack of clear and reliable guidance for the estimation of life expectancy, we retrospectively assessed predictive factors of early death (within 90 days following inclusion) among these patients...
  56. ncbi request reprint Is the maximal tolerated dose still the best primary endpoint? Analysis of 288 dose-seeking phase I trials
    J Bonneterre
    Centre Oscar Lambret, Lille, France
    J Clin Oncol 27:2513. 2009
    ..Recent studies suggest that this policy is not suitable for modern anti-cancer agents...
  57. ncbi request reprint Development and validation of a prediction model for early death among cancer patients participating in phase I clinical trials of new cytotoxic agents
    M E Bonneterre
    Marcq en Baroeul, Marcq en Baroeul, France Centre Oscar Lambret, Lille, France Centre Leon Berard, Lyon, France Institut Claudius Regaud, Toulouse, France
    J Clin Oncol 26:2537. 2008
    ..Given the lack of clear and reliable guidance for the estimation of life expectancy, we retrospectively assessed predictive factors for early death (within 90 days following inclusion) among these patients...
  58. ncbi request reprint Prognostic factors for progression-free and overall survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group
    F Bertucci
    Institut Paoli Calmettes, Marseille, France Centre Leon Berard, Lyon, France Institut Bergonié, Bordeaux, France Centre Oscar Lambret, Lille, France Centre Alexis Vautrin, Nancy, France La Timone University Hospital, Marseille, France Centre Val d Aurelle, Montpellier, France Institut Claudius Regaud, Toulouse, France Centre René Gauducheau, Nantes, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 29:e20506. 2011
    ..e20506 Background: The aim of this work was to investigate factors predicting progression-free survival (PFS) and overall survival (OS) of patients (pts) with advanced GIST treated with 400 mg/day IM included in the BFR14 study...
  59. ncbi request reprint Brain metastasis in metastatic renal cell carcinoma: Predictive factors of occurrence and survival with or without antiangiogenic therapy
    M Vanhuyse
    Centre Oscar Lambret, Lille, France Centre Hospitalier Régional Universitaire de Lille, Lille, France
    J Clin Oncol 29:394. 2011
    ..394 Background: We analyzed renal cell carcinoma (RCC) brain metastasis (BM) risk factors and compared BM occurrence in advanced RCC treated with or without antiangiogenic agents (AAA)...
  60. doi request reprint E-selectin gene S128R polymorphism is associated with poor prognosis in patients with stage II or III colorectal cancer
    Mohamed Hebbar
    Department of Medical Oncology, University Hospital, Lille, France
    Eur J Cancer 45:1871-6. 2009
    ..This polymorphism detection may permit better selection of patients suitable for adjuvant therapy, especially among those with stage II disease...
  61. ncbi request reprint A randomized cross-over trial comparing single-agents capecitabine (C) and UFT plus leucovorin (LV) in patients (Pts) with advanced colorectal cancer (CRC): Preliminary data of a patient preference study
    C Peugniez
    Centre Oscar Lambret, Lille, France Centre Paul Papin, Angers, France Noroncomed Network, Lille, France Centre Hospitalier de Cholet, Cholet, France
    J Clin Oncol 29:558. 2011
    ..To help the physicians to choose between C and U, we initiated this randomized cross-over trial aimed to assess patient's preference...
  62. doi request reprint Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications
    A Italiano
    Department of Medical Oncology, Institut Bergonie, 229 Cours de l Argonne, 33076, Bordeaux Cedex, France
    Target Oncol 8:295-300. 2013
    ..Overall survival is similar to that of younger patients. Comorbidities did not result in increased incidence of toxicity. Careful follow-up regarding tolerance issues should be considered in elderly patients with poor PS...
  63. doi request reprint [Methodological approaches of clinical studies with targeted therapies]
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, 3, rue F Combemale, 59020 Lille, France
    Bull Cancer 95:185-90. 2008
    ..The discontinuation treatment studies and the validation of biomarkers (as surrogate endpoints or as classifiers) are the two main particularities of phase III studies designed for the assessment of molecular targeted therapies...
  64. doi request reprint Individual life expectancy estimation using validated prognostic scores for patients with cancer of unknown primary
    Charles Ferte
    Département de Cancérologie Générale, Centre de lutte contre le cancer Oscar Lambret, Lille, France
    Oncology 78:87-93. 2010
    ..To implement 3 published prognostic scores in an independent set of patients with cancer of unknown primary (CUP), and compare their performance on individual life expectancy prediction...
  65. doi request reprint Publication biases and phase II trials investigating anticancer targeted therapies
    Nicolas Penel
    Medical Oncology, Centre Oscar Lambret, 3 rue Combemale, 59020, Lille, France
    Invest New Drugs 27:287-8. 2009
    ..As a result, we found that the final result of the trial itself was the most important parameter that was related to IF, as the median-IF was significantly lower for negative trials than for positive trials (2.71 vs 6.14, p = 0.004)...
  66. doi request reprint Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis
    Antoine Adenis
    Département de Cancérologie Digestive et Urologique, Centre Oscar Lambret, Lille, France
    Invest New Drugs 28:178-84. 2010
    ..The management of carcinoma of unknown primary site remains debatable. The literature data consists of about 29 phase-II studies investigating 38 regimens, providing a broad range of response rates (RR)...
  67. ncbi request reprint Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Can
    Sylvie Giacchetti
    Hopital Paul Brousse and INSERM, Villejuif, France
    J Clin Oncol 24:3562-9. 2006
    ..In two previous randomized trials, the adjustment of chemotherapy delivery to circadian rhythms improved tolerability and anticancer activity compared with constant-rate infusion during 5 days in patients with metastatic colorectal cancer...
  68. doi request reprint Recurrent priapism related to oxaliplatin infusion
    Antoine Adenis
    J Clin Oncol 26:1016-7. 2008
  69. ncbi request reprint [Clinical Practice Guidelines 2004. Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach: radiotherapy (therapeutic evaluation)]
    Marc Ychou
    Centre Val d Aurelle, Montpellier
    Bull Cancer 92:381-409. 2005
    ..The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients...
  70. ncbi request reprint [Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)]
    Thierry Conroy
    Centre Alexis Vautrin, Nancy
    Bull Cancer 91:759-68. 2004
    ..The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients...
  71. pmc Bevacizumab and postponed suture leakages after surgery for ulcerative colitis and rectal cancer
    Antoine Adenis
    Gut 56:734. 2007
  72. ncbi request reprint Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group
    Jean Yves Blay
    Unité INSERM U590 Centre Léon Bérard and Université Claude Bernard Lyon I and Hopital Edouard Herriot, Lyon, France
    J Clin Oncol 25:1107-13. 2007
    ..Imatinib is the standard treatment of advanced GI stromal tumors (GISTs). It is not known whether imatinib may be stopped in patients in whom disease is controlled...